Strengthen Achieve's Position to Execute Development and Launch of Cytisinicline, if Approved, as the First New Treatment for Nicotine Dependence in Two Decades SEATTLE and VANCOUVER, British Columbia ...
A groundbreaking study conducted by researchers at the University of Copenhagen has revealed that a drug created to treat diabetes and obesity could also hold promise in helping individuals overcome ...
Adare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing CapabilityCompany Reiterates Guidance - If ...
Achieve Life Sciences, Inc. has submitted a New Drug Application (NDA) to the U.S. FDA for cytisinicline, which, if approved, would be the first new pharmacotherapy for nicotine dependence in 20 years ...
SEATTLE and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (ACHV), a late-stage specialty pharmaceutical company focused on the global development and ...
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, announced today the release of a video ...
A world-renowned researcher at Yale University was honored Saturday for her groundbreaking research into nicotine addiction and treatment. Sen. Richard Blumenthal said he will be using research by Dr.
IQWiG has now published its final benefit assessment of bupropion, cytisine, nicotine and varenicline for smoking cessation, also in combination with each other, compared with no drug therapy.
Concurrent Cisplatin, Etoposide, and Chest Radiotherapy in Pathologic Stage IIIB Non–Small-Cell Lung Cancer: A Southwest Oncology Group Phase II Study, SWOG 9019 PURPOSE: There is a current lack of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results